Calithera Biosciences, Inc. (NASDAQ:CALA) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday.
A number of other research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price (up from $14.00) on shares of Calithera Biosciences in a research note on Monday, June 12th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $20.00 target price (up from $15.00) on shares of Calithera Biosciences in a research note on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $15.50.
Shares of Calithera Biosciences (NASDAQ CALA) opened at 13.90 on Friday. The stock’s market capitalization is $493.12 million. The stock’s 50 day moving average is $15.88 and its 200 day moving average is $12.74. Calithera Biosciences has a 52 week low of $2.20 and a 52 week high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.14. The firm had revenue of $7.26 million during the quarter, compared to analyst estimates of $4.80 million. Analysts anticipate that Calithera Biosciences will post ($0.83) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Calithera Biosciences, Inc. (CALA) Stock Rating Lowered by BidaskClub” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/08/14/calithera-biosciences-inc-cala-stock-rating-lowered-by-bidaskclub.html.
In other Calithera Biosciences news, VP Keith Orford sold 2,120 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $18.31, for a total value of $38,817.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 3,470 shares of company stock valued at $61,817. Insiders own 16.30% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. Teachers Retirement System of The State of Kentucky increased its stake in shares of Calithera Biosciences by 49.2% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 27,600 shares of the biotechnology company’s stock worth $410,000 after buying an additional 9,100 shares during the period. FMR LLC increased its stake in shares of Calithera Biosciences by 85.8% in the second quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock worth $40,349,000 after buying an additional 1,254,900 shares during the period. Vanguard Group Inc. increased its stake in shares of Calithera Biosciences by 29.7% in the second quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock worth $17,813,000 after buying an additional 274,510 shares during the period. Northern Trust Corp increased its stake in shares of Calithera Biosciences by 1,355.1% in the second quarter. Northern Trust Corp now owns 337,640 shares of the biotechnology company’s stock worth $5,014,000 after buying an additional 314,436 shares during the period. Finally, Citigroup Inc. increased its stake in shares of Calithera Biosciences by 5,957.9% in the second quarter. Citigroup Inc. now owns 42,405 shares of the biotechnology company’s stock worth $630,000 after buying an additional 41,705 shares during the period. 54.51% of the stock is owned by hedge funds and other institutional investors.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.